Checkpoint Therapeutics (CKPT) Projected to Post Quarterly Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT) is expected to issue its quarterly earnings data before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT opened at $4.06 on Thursday. Checkpoint Therapeutics has a 12-month low of $1.38 and a 12-month high of $4.50. The company has a market cap of $198.26 million, a PE ratio of -2.21 and a beta of 1.41. The stock has a 50 day simple moving average of $3.29 and a 200-day simple moving average of $3.23.

Analyst Ratings Changes

CKPT has been the topic of a number of research analyst reports. Lake Street Capital reissued a “hold” rating and set a $4.10 price target (down from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. D. Boral Capital reissued a “buy” rating and set a $4.80 target price (down previously from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, HC Wainwright restated a “neutral” rating and set a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Insider Activity

In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 9,233 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $3.41, for a total value of $31,484.53. Following the transaction, the chief executive officer now owns 3,785,350 shares of the company’s stock, valued at approximately $12,908,043.50. This represents a 0.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William Garrett Gray sold 74,110 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the sale, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at approximately $5,353,223.48. This represents a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,674 shares of company stock worth $336,011 over the last 90 days. 2.10% of the stock is currently owned by company insiders.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.